Drug Trial Radar · NCT07769242
A Phase I/II Clinical Trials of SHR-8203 Injection in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Sep 22, 2026
Primary completion
Dec 30, 2029
Study completion Dec 30, 2029
Sponsor
- Lead sponsor
- Beijing Suncadia Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a multicenter, open-label Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and efficacy of SHR-8203 injection in participants with advanced solid tumors.
Conditions
- Solid Tumors
Interventions
SHR-8203 InjectionDrug
SHR-8203 injection, in Dose 1/ Dose 2/ Dose 3/ Dose 4.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of subjects with dose-limiting toxicity (DLT)Time frame: From first dose of study treatment until the end of Cycle 1(up to 21 days)
- Incidence and severity of adverse events (AEs)Time frame: From the first visit to the end of the safety follow-up period (1 year)
- Maximum Tolerated Dose (MTD)Time frame: During the DLT observation period, the dose level at which the estimated toxicity probability was closest to the target toxicity probability (i.e., 0.3) (up to 21 days)
- Determination of Recommended Phase II dose (RP2D)Time frame: After dose optimization, sufficient safety, tolerability, PK and preliminary efficacy results were obtained, and the dose selected for the subsequent indication expansion stage was confirmed by SRC discussion (1 year).
- Objective Response Rate (ORR)Time frame: From time of first dose of SHR-8203 until the date of objective disease progression or death (1 year)
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Macquarie University Clinical Trials Unit
Macquarie Park, New South Wales, Australia · Not yet recruiting
Scientia Clinical Research Ltd
Randwick, New South Wales, Australia · Not yet recruiting
ICON Cancer Centre South Brisbane
South Brisbane, Queensland, Australia · Not yet recruiting
Southern Oncology Clinical Research Unit (SOCRU)
Bedford Park, South Australia, Australia · Not yet recruiting
St John of God Subiaco Hospital
Subiaco, Western Australia, Australia · Not yet recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.